Cargando…
CD47‐SIRPα blocking‐based immunotherapy: Current and prospective therapeutic strategies
BACKGROUND: The CD47‐signal regulatory protein alpha (SIRPα) ‘don't eat me’ signalling axis is perhaps the most prominent innate immune checkpoint to date. However, from initial clinical trials, it is evident that monotherapy with CD47‐SIRPα blocking has a limited therapeutic effect at the maxi...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9339239/ https://www.ncbi.nlm.nih.gov/pubmed/35908284 http://dx.doi.org/10.1002/ctm2.943 |